Literature DB >> 24235126

Risky business: target choice in adoptive cell therapy.

Richard A Morgan1.   

Abstract

In this issue of Blood, Casucci et al present an elegant study that describes a potential new target for adoptive cell transfer (ACT), in this case CD44 splice variant 6 (CD44v6), and detail why it may be a good target for ACT and how to manage expected off-tumor/on-target toxicities.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24235126      PMCID： PMC3829111          DOI： 10.1182/blood-2013-09-527622

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  8 in total

1.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

Authors:  James N Kochenderfer; Mark E Dudley; Steven A Feldman; Wyndham H Wilson; David E Spaner; Irina Maric; Maryalice Stetler-Stevenson; Giao Q Phan; Marybeth S Hughes; Richard M Sherry; James C Yang; Udai S Kammula; Laura Devillier; Robert Carpenter; Debbie-Ann N Nathan; Richard A Morgan; Carolyn Laurencot; Steven A Rosenberg
Journal:  Blood       Date:  2011-12-08       Impact factor: 22.113

2.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

Authors:  Paul F Robbins; Richard A Morgan; Steven A Feldman; James C Yang; Richard M Sherry; Mark E Dudley; John R Wunderlich; Azam V Nahvi; Lee J Helman; Crystal L Mackall; Udai S Kammula; Marybeth S Hughes; Nicholas P Restifo; Mark Raffeld; Chyi-Chia Richard Lee; Catherine L Levy; Yong F Li; Mona El-Gamil; Susan L Schwarz; Carolyn Laurencot; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

3.  CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma.

Authors:  Monica Casucci; Benedetta Nicolis di Robilant; Laura Falcone; Barbara Camisa; Margherita Norelli; Pietro Genovese; Bernhard Gentner; Fabiana Gullotta; Maurilio Ponzoni; Massimo Bernardi; Magda Marcatti; Aurore Saudemont; Claudio Bordignon; Barbara Savoldo; Fabio Ciceri; Luigi Naldini; Gianpietro Dotti; Chiara Bonini; Attilio Bondanza
Journal:  Blood       Date:  2013-09-09       Impact factor: 22.113

4.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors:  Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2013-03-25       Impact factor: 91.245

Review 5.  Cancer/testis (CT) antigens: potential targets for immunotherapy.

Authors:  Otavia L Caballero; Yao-Tseng Chen
Journal:  Cancer Sci       Date:  2009-08-01       Impact factor: 6.716

Review 6.  EGF receptor variant III as a target antigen for tumor immunotherapy.

Authors:  Gordon Li; Albert J Wong
Journal:  Expert Rev Vaccines       Date:  2008-09       Impact factor: 5.217

7.  CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.

Authors:  Renier J Brentjens; Marco L Davila; Isabelle Riviere; Jae Park; Xiuyan Wang; Lindsay G Cowell; Shirley Bartido; Jolanta Stefanski; Clare Taylor; Malgorzata Olszewska; Oriana Borquez-Ojeda; Jinrong Qu; Teresa Wasielewska; Qing He; Yvette Bernal; Ivelise V Rijo; Cyrus Hedvat; Rachel Kobos; Kevin Curran; Peter Steinherz; Joseph Jurcic; Todd Rosenblat; Peter Maslak; Mark Frattini; Michel Sadelain
Journal:  Sci Transl Med       Date:  2013-03-20       Impact factor: 17.956

8.  Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.

Authors:  Paul F Robbins; Yong-Chen Lu; Mona El-Gamil; Yong F Li; Colin Gross; Jared Gartner; Jimmy C Lin; Jamie K Teer; Paul Cliften; Eric Tycksen; Yardena Samuels; Steven A Rosenberg
Journal:  Nat Med       Date:  2013-05-05       Impact factor: 53.440
  8 in total
  3 in total

Review 1.  Trial Watch: Adoptive cell transfer for oncological indications.

Authors:  Fernando Aranda; Aitziber Buqué; Norma Bloy; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-05-05       Impact factor: 8.110

Review 2.  The Cancer Cell Dissemination Machinery as an Immunosuppressive Niche: A New Obstacle Towards the Era of Cancer Immunotherapy.

Authors:  Saeed Asiry; Gina Kim; Panagiota S Filippou; Luis Rivera Sanchez; David Entenberg; Douglas K Marks; Maja H Oktay; George S Karagiannis
Journal:  Front Immunol       Date:  2021-04-13       Impact factor: 7.561

Review 3.  T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology.

Authors:  Michaela E Sharpe
Journal:  Toxicol Pathol       Date:  2018-02       Impact factor: 1.902
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.